nach oben

Drugs

Erschienen in:

01.09.2006 | Leading Article

The Role of Topical Immune Response Modifiers in Skin Cancer

verfasst von: Courtney Woodmansee, Jessica Pillow, Dr Robert B. Skinner Jr

Erschienen in: Drugs | Ausgabe 13/2006

Einloggen, um Zugang zu erhalten

Abstract

Topical immune response modifiers include imiquimod and resiquimod. The mechanism of action of immune response modifiers is complex and not completely understood. It involves the stimulation of innate and cell-mediated immune responses through Toll-like receptor-mediated induction of cytokines. Imiquimod is approved for the treatment of actinic keratoses, superficial basal cell carcinomas and warts; it has also been documented to successfully treat other forms of skin cancer such as squamous cell carcinoma in situ, melanoma and extramammary Paget’s disease.

3M Pharmaceuticals. Aldara™ (imiquimod) cream, 5%. Package insert. St. Paul (MN): 3M Pharmaceuticals, 2005

Gaspari AA, Sauder DN. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg 2003; 29: 1027–34PubMedCrossRef

Hengge UR, Ruzicka T. Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg 2004; 30: 1101–12PubMedCrossRef

Berman B, Villa A. Immune response modulators in the treatment of skin cancer. In: Friedman RJ, Dzubow LM, editors. Cancer of the skin. Philadelphia (PA): Elsevier Saunders, 2005: 499–513

Berman B, Sullivan T, De Araujo T, et al. Expression of Fasreceptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003; 149 Suppl. 66: 59–61CrossRef

Schön M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138–49PubMedCrossRef

Schön MP, Wienrich BG, Drewniok C, et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122: 1266–76PubMedCrossRef

Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratoses: results from two phase III trials, randomized, double blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714–21PubMedCrossRef

Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind vehicle-controlled study to assess 5% imiquimod cream for the treatment of actinic keratoses. Arch Dermatol 2002 Nov; 138: 1498–502PubMedCrossRef

10.

Stockfleth E, Christophers E, Benninghoff B, et al. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004 Dec; 140: 1542PubMedCrossRef

11.

Lee P, Harwell W, Loven K, et al. Long-term clinical outcomes following treatment of actinic keratoses with imiquimod 5% cream. Dermatol Surg 2005; 31: 659–63PubMedCrossRef

12.

Salasche S, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002 Oct; 47(4): 571–7PubMedCrossRef

13.

Smith K, Germain M, Yeager J, et al. Topical 5% imiquimod for the therapy of actinic cheilitis. J Am Acad Dermatol 2002 Oct; 47(4): 497–501PubMedCrossRef

14.

Mackenzie-Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen’s disease. J Am Acad Dermatol 2001; 44(3): 462–70PubMedCrossRef

15.

Orengo I, Rosen T, Guill C. Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J Am Acad Dermatol 2002; 47(4): 225–8CrossRef

16.

Schroeder T, Sengelmann R. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 2002 Apr; 46(4): 545–8PubMedCrossRef

17.

Pehoushek J, Smith K. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol 2001 Jan; 137: 14–6PubMed

18.

Smith K, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen’s disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorocuracil. Dermatol Surg 2001 Jun; 27(6): 560–4CrossRef

19.

Petrow W, Gerdsen R, Urlich M, et al. Successful topical immunotherapy for bowenoid papulosis with imiquimod. Br J Dermatol 2001; 145: 1022–36PubMedCrossRef

20.

Preston D, Stern R. Nonmelanoma cancers of the skin. N Engl J Med 1992 Dec 3; 327(23): 1649–62PubMedCrossRef

21.

Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999 Dec; 41(6): 1002–7PubMedCrossRef

22.

Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001 May; 44(5): 807–13PubMedCrossRef

23.

Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002 Sep; 47(3): 390–8PubMedCrossRef

24.

Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227–36PubMedCrossRef

25.

Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Arch Dermatol 2002 Sep; 138: 1165–71PubMedCrossRef

26.

Wolf IH, Cerroni L, Kodama K, et al. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005 Apr; 141: 510–4PubMedCrossRef

27.

Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143: 843–5PubMedCrossRef

28.

Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 Suppl. 66: 66–9CrossRef

29.

Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol 2003 Jul; 139: 945–7PubMedCrossRef

30.

Steinmann A, Funk JO, Schuler G, et al. Topical imiquimod treatment of a cutaneous melanoma metastasis [letter]. J Am Acad Dermatol 2000 Sep; 43(3): 555–6PubMed

31.

Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003 Mar; 139: 273–6PubMedCrossRef

32.

Qian Z, Zeitoun NC, Shieh S, et al. Successful treatment of extramammary Paget’s disease with imiquimod. J Drugs Dermatol 2003 Jan; 2(1): 73–6PubMed

33.

Zampogna JC, Flowers FP, Roth WI, et al. Treatment of primary limited cutaneous extramammary Paget’s disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 2002 Oct; 47: 229–35CrossRef

34.

Saunder DN, Smith MH, Senta-McMillian T, et al. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother 2003 Dec; 47: 3846–52CrossRef

35.

Del Rosso J. Therapy for cutaneous epithelial malignancy: a review of research, development, current status and practical use of topical imiquimod. Skin Aging 2003; 11: 44–54

Titel: The Role of Topical Immune Response Modifiers in Skin Cancer
verfasst von: Courtney Woodmansee
Jessica Pillow
Dr Robert B. Skinner Jr
Publikationsdatum: 01.09.2006
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 13/2006
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200666130-00001

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2006

Immunotherapy for De Novo Renal Transplantation

Extended-Release Intramuscular Naltrexone

Extended-Release Intramuscular Naltrexone

Extended-Release Intramuscular Naltrexone

Management of Focal-Onset Seizures

Extended-Release Intramuscular Naltrexone